Drug/Small Molecule:
cetuximab

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.



last updated 10/25/2013

FDA Label for cetuximab and EGFR, KRAS

This label is on the FDA Biomarker List
Genetic testing required

Summary

Cetuximab is used in alone or in combination therapy to treat advanced squamous cell carcinoma of the head and neck and to treat K-Ras mutation-negative, EGFR expressing metastatic colorectal cancer. In cases of colorectal cancer, the label states "Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment."

Annotation

Excerpt from the cetuximab (Erbitux) drug label:

Erbitux is indicated for the treatment of K-Ras mutation-negative (wild-type), epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use.

Determination of K-Ras mutational status in colorectal tumors using an FDA-approved test indicated for this use is necessary for selection of patients for treatment with Erbitux. Erbitux is indicated only for patients with EGFR-expressing K-Ras mutation-negative (wild-type) mCRC.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the cetuximab (Erbitux) drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Carcinoma, Non-Small-Cell Lung
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Colorectal Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • EGFR
    • Indications & usage section, Dosage & administration section, Description section, Clinical pharmacology section, Clinical studies section, Warnings and precautions section, efficacy
    • source: FDA Label
  • KRAS
    • Indications & usage section, Dosage & administration section, Clinical pharmacology section, Clinical studies section, Warnings and precautions section
    • source: FDA Label

last updated 10/25/2013

European Medicines Agency (EMA) Label for cetuximab and EGFR, KRAS

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of Cetuximab (Erbitux) in colorectal cancer patients with tumors with KRAS mutations or if tumor status is not known.

Annotation

Excerpt from the Cetuximab (Erbitux) EPAR:

Colorectal cancer patients with KRAS mutated tumours Cetuximab should not be used in the treatment of colorectal cancer patients whose tumours have KRAS mutations or for whom KRAS tumour status is unknown. Results from clinical studies show a negative benefit-risk balance in tumours with KRAS mutations. In particular, in these patients negative effects on progression-free survival (PFS) and overall survival (OS) were seen as add-on to FOLFOX4 (see section 5.1). Similar findings were also reported when cetuximab was given as add-on to XELOX in combination with bevacizumab (CAIRO2). However, in this study no positive effects on PFS or OS were demonstrated in patients with KRAS wild-type tumours, either.

This information is highlighted in the following sections:
Therapeutic indications, posology and method of administration, contraindications, pharmacodynamic properties, special warnings and precautions for use, package leaflet: information for the user.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Cetuximab EMA drug label.

*Disclaimer: The contents of this page have not been endorsed by the EMA and are the sole responsibility of PharmGKB.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?
therascreen KRAS RGQ PCR Kit KRAS KRAS:Gly12Asp , KRAS KRAS:Gly12Ala , KRAS KRAS:Gly12Val , KRAS KRAS:Gly12Ser , KRAS KRAS:Gly12Arg , KRAS KRAS:Gly12Cys , KRAS KRAS:Gly13Asp
KRAS Mutation Detection Kit - Mutector II KRAS KRAS:Gly12Asp , KRAS KRAS:Gly12Ala , KRAS KRAS:Gly12Val , KRAS KRAS:Gly12Ser , KRAS KRAS:Gly12Arg , KRAS KRAS:Gly12Cys , KRAS KRAS:Gly13Asp , KRAS KRAS:Gly13Ser , KRAS KRAS:Gly13Arg , KRAS KRAS:Gly13Cys , KRAS KRAS:Gly13Ala , KRAS KRAS:Gly13Val

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs10034692 15630454A>G, 37578A>G, 75419787A>G
A > G
Not Available
No VIP available No Clinical Annotations available VA
rs1017733 *1825C>T, 15463017C>T, 75252350C>T
C > T
3' UTR
No VIP available No Clinical Annotations available VA
rs11568315 55020563_55020564CA[9][14][15][16][17][18][19][20][21][22][23]
CACACACACACACACACACACACACACACA > 15
CACACACACACACACACACACACACACACA > 16
CACACACACACACACACACACACACACACA > 17
CACACACACACACACACACACACACACACA > 18
CACACACACACACACACACACACACACACA > 22
CACACACACACACACACACACACACACACA > 23
CACACACACACACACACACACACACACACA > (CA)9
CACACACACACACACACACACACACACACA > 14
CACACACACACACACACACACACACACACA > 20
CACACACACACACACACACACACACACACA > 21
CACACACACACACACACACACACACACACA > 19
Not Available
No VIP available No Clinical Annotations available VA
rs11568972 110889007A>C, 1450-1120A>C, 1576-1120A>C, 35436728A>C, 59968A>C
A > C
Intronic
No VIP available No Clinical Annotations available VA
rs11568993 110897315C>T, 1851C>T, 1977C>T, 35445036C>T, 68276C>T, Cys617=, Cys659=
C > T
Synonymous
Cys659Cys
No VIP available No Clinical Annotations available VA
rs11725706 15538775G>A, 75328108G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs11942466 15632745C>A, 39869C>A, 75422078C>A
C > A
Not Available
No VIP available No Clinical Annotations available VA
rs13104811 13103G>A, 15605979G>A, 75395312G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs1353295 15539789G>A, 75329122G>A
G > A
Not Available
No VIP available No Clinical Annotations available VA
rs1801160 129-825C>T, 2194G>A, 620696G>A, 67742838C>T, 97770920C>T, Val732Ile
C > T
Missense
Val732Ile
No VIP available No Clinical Annotations available VA
rs1801274 12968387A>G, 161479745A>G, 497A>G, 500A>G, 9541A>G, FCGR2A:His131Arg
A > G
Missense
His167Arg
No VIP available No Clinical Annotations available VA
rs2074390 110910016G>A, 2608+151G>A, 2734+151G>A, 35457737G>A, 80977G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs2132065 15535971A>T, 75325304A>T
A > T
Not Available
No VIP available CA VA
rs2227983 147531G>A, 147531G>C, 147531G>T, 1562G>A, 1562G>C, 1562G>T, 4818624G>A, 4818624G>C, 4818624G>T, 55229255G>A, 55229255G>C, 55229255G>T, Arg521Lys, Arg521Met, Arg521Thr, EGFR: 497G/A, EGFR:1562G>A, EGFR:R497K, R497K, R521K
G > A
G > T
G > C
Missense
Arg521Thr
Arg521Lys
Arg521Met
No VIP available No Clinical Annotations available VA
rs2297595 226525A>G, 496A>G, 68137009T>C, 98165091T>C, DPYD:496A>G, DPYD:Met166Val, Met166Val
T > C
Missense
Met166Val
No VIP available No Clinical Annotations available VA
rs3913032 15547526A>C, 75336859A>C
A > C
Not Available
No VIP available No Clinical Annotations available VA
rs3918290 1905+1G>A, 476002G>A, 67887532C>T, 97915614C>T, DPYD*2A, DPYD:67887533 G>A, DPYD:IVS14 + 1G>A
C > T
Donor
No VIP available CA VA
rs396991 10872T>G, 13003184A>C, 158V/F, 161514542A>C, 176F/V, 523T>G, 526T>G, 631T>G, 634T>G, A559C, FCGR3A: V158F, Phe175Val, Phe176Val, Phe211Val, Phe212Val, T559G
A > C
Missense
Phe175Val
No VIP available CA VA
rs4444903 -382A>G, 110834110A>G, 35381831A>G, 5071A>G
A > G
5' UTR
No VIP available No Clinical Annotations available VA
rs4698803 110914427A>T, 2633A>T, 2735-1462A>T, 2759A>T, 35462148A>T, 85388A>T, Glu878Val, Glu920Val
A > T
Missense
Glu920Val
No VIP available No Clinical Annotations available VA
rs56038477 1236G>A, 352197G>A, 68011337C>T, 98039419C>T, Glu412=
C > T
Synonymous
Glu412Glu
No VIP available CA VA
rs61764370 *2505T>G, *2626T>G, 18120348A>C, 25360224A>C, 48631T>G
A > C
3' UTR
No VIP available No Clinical Annotations available VA
rs6447003 15597581G>C, 4705G>C, 75386914G>C
G > C
Not Available
No VIP available No Clinical Annotations available VA
rs6533485 110927563G>C, 3166-1745G>C, 3169-1745G>C, 3292-1745G>C, 35475284G>C, 98524G>C
G > C
Intronic
No VIP available CA VA
rs67376798 2846A>T, 67519865T>A, 843669A>T, 97547947T>A, Asp949Val
T > A
Missense
Asp949Val
No VIP available No Clinical Annotations available VA
rs6850557 110911015G>A, 2608+1150G>A, 2734+1150G>A, 35458736G>A, 81976G>A
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs712829 -216G>T, 216G>T, 4676124G>T, 5031G>T, 55086755G>T, EGFR:-216G>T
G > T
5' UTR
No VIP available No Clinical Annotations available VA
rs712830 -191A>C, 191C>A, 4676149A>C, 5056A>C, 55086780A>C, EGFR:
A > C
5' UTR
No VIP available No Clinical Annotations available VA
rs7687621 15460493T>C, 429-618T>C, 75249826T>C
T > C
Intronic
No VIP available No Clinical Annotations available VA
rs929446 110883344C>T, 1186+203C>T, 1312+203C>T, 35431065C>T, 54305C>T
C > T
Intronic
No VIP available CA VA
rs9344 *1365+4648C>T, 12038G>A, 14768705G>A, 69462910G>A, 723G>A, CCND1 (A870G), CCND1:870G>A, Pro241=, rs603965
G > A
Intronic
Pro241Pro
No VIP available No Clinical Annotations available VA
rs9996584 15632628A>G, 39752A>G, 75421961A>G
A > G
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Generic Names
  • Anti EGFR
  • IMC-C225
  • cetuximab
Trade Names
  • Erbitux
  • Erbitux (ImClone Systems Inc)
Brand Mixture Names

PharmGKB Accession Id:
PA10040

Description

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Source: Drug Bank

Indication

For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.

Source: Drug Bank

Pharmacology

Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Half-Life

114 hrs

Source: Drug Bank

Toxicity

Single doses of cetuximab higher than 500 mg/m 2 have not been tested. There is no experience with overdosage in human clinical trials.

Source: Drug Bank

Chemical Properties

Chemical Formula

C6484H10042N1732O2023S36

Source: Drug Bank

Canonical SMILES

Not Available

Source: Drug Bank

Average Molecular Weight

145781.6000

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
C1QA (source: Drug Bank)
C1QB (source: Drug Bank)
C1QC (source: Drug Bank)
C1R (source: Drug Bank)
C1S (source: Drug Bank)
EGFR (source: Drug Bank)
FCGR1A (source: Drug Bank)
FCGR2A (source: Drug Bank)
FCGR2B (source: Drug Bank)
FCGR2C (source: Drug Bank)
FCGR3A (source: Drug Bank)
FCGR3B (source: Drug Bank)
No related drugs are available.

Curated Information ?

Publications related to cetuximab: 36

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. The pharmacogenomics journal. 2014. Loupakis F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics. 2014. Liu Mou-Ze, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013. Ciriello Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenetics and genomics. 2013. Hodoglugil Ugur, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. The pharmacogenomics journal. 2013. Sebio A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenetics and genomics. 2013. Sebio Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013. Weng Liming, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. The pharmacogenomics journal. 2013. Negri F V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection. PloS one. 2013. Kitano Shiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. The pharmacogenomics journal. 2012. Savonarola A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. British journal of clinical pharmacology. 2012. Etienne-Grimaldi Marie-Christine, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. The pharmacogenomics journal. 2011. Parmar S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Hu-Lieskovan Siwen, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Deenen Maarten J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Kim Jin C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. The Journal of pathology. 2011. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer. 2011. Dahan Laetitia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic contribution to drug response. Cancer journal (Sudbury, Mass.). 2011. Watson Roshawn G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. The pharmacogenomics journal. 2010. Graziano F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical pharmacology and therapeutics. 2010. Stegmeier F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and biomarkers in colorectal cancer. The pharmacogenomics journal. 2009. Strimpakos A S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. The pharmacogenomics journal. 2009. Graziano F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine. 2008. Karapetis Christos S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Graziano Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007. Liu Wanqing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cetuximab for the treatment of colorectal cancer. The New England journal of medicine. 2007. Jonker Derek J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Zhang Wu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British journal of cancer. 2007. Di Fiore F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics. 2007. Vincenzi Bruno, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. PubMed

LinkOuts

GenBank:
J00228
Web Resource:
Wikipedia
National Drug Code Directory:
66733-948-23
DrugBank:
DB00002
Therapeutic Targets Database:
DNC000788
FDA Drug Label at DailyMed:
8bc6397e-4bd8-4d37-a007-a327e4da34d9

Clinical Trials

These are trials that mention cetuximab and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.